Integrated Investment Consultants’s Teva Pharmaceuticals TEVA Stock Holding History

Integrated Investment Consultants’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-730	Closed	-$12K	–	631
2018 Q1	$12K	Buy	+730	New	+$14.3K	﹤0.01%	601
2017 Q3	$13K	Hold	730	–	–	0.01%	499
2017 Q2	$24K	Hold	730	–	–	0.01%	452
2017 Q1	$23K	Hold	730	–	–	0.01%	446
2016 Q4	$26K	Hold	730	–	–	0.01%	437
2016 Q3	$32K	Hold	730	–	–	0.02%	422
2016 Q2	$37K	Hold	730	–	–	0.02%	421
2016 Q1	$41K	Buy	+730	New	+$42.8K	0.02%	375

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Integrated Investment Consultants's TEVA Position: Q2 2018 in Review

Integrated Investment Consultants sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 730 shares — an estimated $12K sold.

Integrated Investment Consultants first reported a position in TEVA in Q1 2016 and held it in 8 quarters. The position peaked at $41K in Q1 2016. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

Integrated Investment Consultants reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Integrated Investment Consultants sold 730 Teva Pharmaceuticals shares in Q2 2018, an estimated $12K.
Integrated Investment Consultants first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Integrated Investment Consultants's Teva Pharmaceuticals position peaked at $41K in Q1 2016.
539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Integrated Investment Consultants's 13F filing for Q2 2018, filed 1 Aug 2018.